Literature DB >> 24345255

Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.

James H Flory1, Dylan S Small, Patricia A Cassano, David J Brillon, Alvin I Mushlin, Sean Hennessy.   

Abstract

AIMS: To provide evidence on the comparative effectiveness of oral diabetes drug combinations.
METHODS: We performed a retrospective, observational cohort study of glycosylated hemoglobin change in outpatients newly exposed to dual- or triple-drug oral diabetes treatment.
RESULTS: Adjusted response to a second drug added to metformin ranged from 0.85 to 1.21% glycosylated hemoglobin decline. Response to a third drug was smaller (0.53-0.91%). Higher baseline glycosylated hemoglobin was associated with larger response; sulfonylurea effectiveness declined over time; and thiazolidinediones were more effective in obese patients and women.
CONCLUSION: Observational data provide results qualitatively consistent with the limited available randomized data on diabetes drug effectiveness, and extend these findings into common clinical scenarios where randomized data are unavailable. Sex and BMI influence the comparative effectiveness of diabetes drug combinations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24345255      PMCID: PMC3996558          DOI: 10.2217/cer.13.87

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  20 in total

1.  A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes.

Authors:  G C Hall; A D McMahon; M-P Dain; P D Home
Journal:  Diabetes Res Clin Pract       Date:  2011-10-02       Impact factor: 5.602

Review 2.  Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.

Authors:  K Esposito; P Chiodini; G Bellastella; M I Maiorino; D Giugliano
Journal:  Diabetes Obes Metab       Date:  2011-11-03       Impact factor: 6.577

3.  Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Linda L Humphrey; Donna E Sweet; Melissa Starkey; Paul Shekelle
Journal:  Ann Intern Med       Date:  2012-02-07       Impact factor: 25.391

4.  Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.

Authors:  T A Jones; M Sautter; L F Van Gaal; N P Jones
Journal:  Diabetes Obes Metab       Date:  2003-05       Impact factor: 6.577

5.  Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

Authors:  Olivia J Phung; Jennifer M Scholle; Mehak Talwar; Craig I Coleman
Journal:  JAMA       Date:  2010-04-14       Impact factor: 56.272

6.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

7.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

Review 8.  Metformin: effective and safe in renal disease?

Authors:  William Guy Herrington; Jeremy B Levy
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

9.  Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Authors:  Daniel J Drucker; Steven I Sherman; Fred S Gorelick; Richard M Bergenstal; Robert S Sherwin; John B Buse
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

10.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2009-11-10       Impact factor: 2.373

View more
  9 in total

1.  Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.

Authors:  James H Flory; Alvin I Mushlin
Journal:  J Clin Epidemiol       Date:  2014-11-26       Impact factor: 6.437

2.  Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.

Authors:  James Flory; Kevin Haynes; Charles E Leonard; Sean Hennessy
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 3.  Sex differences in type 2 diabetes: focus on disease course and outcomes.

Authors:  Lisa Arnetz; Neda Rajamand Ekberg; Michael Alvarsson
Journal:  Diabetes Metab Syndr Obes       Date:  2014-09-16       Impact factor: 3.168

4.  Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis.

Authors:  S M Sheikh Ghadzi; M O Karlsson; M C Kjellsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-09-25

5.  Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.

Authors:  Girish Parthan; Shobhit Bhansali; Anura V Kurpad; Rama Walia; Kishor Bhat; Anil Bhansali
Journal:  BMC Pharmacol Toxicol       Date:  2018-07-03       Impact factor: 2.483

6.  Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.

Authors:  Hae Jin Kim; In Kyung Jeong; Kyu Yeon Hur; Soo-Kyung Kim; Jung Hyun Noh; Sung Wan Chun; Eun Seok Kang; Eun-Jung Rhee; Sung Hee Choi
Journal:  Diabetes Metab J       Date:  2022-03-17       Impact factor: 5.893

7.  Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.

Authors:  John M Dennis; William E Henley; Michael N Weedon; Mike Lonergan; Lauren R Rodgers; Angus G Jones; William T Hamilton; Naveed Sattar; Salim Janmohamed; Rury R Holman; Ewan R Pearson; Beverley M Shields; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2018-08-02       Impact factor: 19.112

8.  AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion.

Authors:  Qiuyu Wang; Chunlin Zhao; Lili Jin; Hanyu Zhang; Qifan Miao; Hongsheng Liu; Dianbao Zhang
Journal:  Int J Mol Sci       Date:  2018-10-07       Impact factor: 5.923

Review 9.  Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA).

Authors:  Peter R Rehani; Hanaa Iftikhar; Motowo Nakajima; Tohru Tanaka; Zaid Jabbar; Riyadh N Rehani
Journal:  J Diabetes Res       Date:  2019-11-06       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.